Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
As of close of business last night, Tandem Diabetes Care Inc’s stock clocked out at $10.84, up 0.18% from its previous closing price of $10.82. In other words, the price has increased by $0.18 from its previous closing price. On the day, 2.34 million shares were traded. TNDM stock price reached its highest trading level at $11.295 during the session, while it also had its lowest trading level at $10.745.
Ratios:
To gain a deeper understanding of TNDM’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.88 and its Current Ratio is at 2.44. In the meantime, Its Debt-to-Equity ratio is 3.37 whereas as Long-Term Debt/Eq ratio is at 3.22.
On August 07, 2025, Piper Sandler Downgraded its rating to Neutral which previously was Overweight but kept the price unchanged to $14.
Citigroup Downgraded its Neutral to Sell on July 09, 2025, while the target price for the stock was maintained at $14.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 11 ’25 when Sheridan John F bought 10,000 shares for $10.23 per share. The transaction valued at 102,318 led to the insider holds 106,327 shares of the business.
Vosseller Leigh bought 13,720 shares of TNDM for $149,404 on Aug 08 ’25. The EVP & CHIEF FINANCIAL OFFICER now owns 25,580 shares after completing the transaction at $10.89 per share. On Mar 07 ’25, another insider, Kyrillos Jean-Claude, who serves as the EVP & Chief Operating Officer of the company, bought 10,538 shares for $18.12 each. As a result, the insider paid 190,966 and bolstered with 10,538 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TNDM now has a Market Capitalization of 732453440 and an Enterprise Value of 871000064. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.73 while its Price-to-Book (P/B) ratio in mrq is 5.49. Its current Enterprise Value per Revenue stands at 0.87 whereas that against EBITDA is -11.477.
Stock Price History:
The Beta on a monthly basis for TNDM is 1.45, which has changed by -0.7414739 over the last 52 weeks, in comparison to a change of 0.15222645 over the same period for the S&P500. Over the past 52 weeks, TNDM has reached a high of $47.60, while it has fallen to a 52-week low of $9.98. The 50-Day Moving Average of the stock is -34.17%, while the 200-Day Moving Average is calculated to be -55.86%.
Shares Statistics:
It appears that TNDM traded 1.92M shares on average per day over the past three months and 3757900 shares per day over the past ten days. A total of 67.53M shares are outstanding, with a floating share count of 66.90M. Insiders hold about 1.00% of the company’s shares, while institutions hold 120.69% stake in the company. Shares short for TNDM as of 1753920000 were 8746041 with a Short Ratio of 4.56, compared to 1751241600 on 9752133. Therefore, it implies a Short% of Shares Outstanding of 8746041 and a Short% of Float of 17.950001.
Earnings Estimates
The company has 21.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.09, with high estimates of $0.05 and low estimates of -$0.23.
Analysts are recommending an EPS of between -$1.33 and -$3.43 for the fiscal current year, implying an average EPS of -$2.21. EPS for the following year is -$0.89, with 23.0 analysts recommending between -$0.29 and -$1.97.
Revenue Estimates
In the current quarter, 19 analysts expect revenue to total $236.94M. It ranges from a high estimate of $250.3M to a low estimate of $233.21M. As of the current estimate, Tandem Diabetes Care Inc’s year-ago sales were $243.97MFor the next quarter, 19 analysts are estimating revenue of $285.82M. There is a high estimate of $292.16M for the next quarter, whereas the lowest estimate is $266.57M.
A total of 22 analysts have provided revenue estimates for TNDM’s current fiscal year. The highest revenue estimate was $1.08B, while the lowest revenue estimate was $978.37M, resulting in an average revenue estimate of $1B. In the same quarter a year ago, actual revenue was $940.2MBased on 22 analysts’ estimates, the company’s revenue will be $1.1B in the next fiscal year. The high estimate is $1.15B and the low estimate is $1.06B.
